JW Pharma re­leases cancer treat­ment trial re­sults

BioSpectrum (Asia) - - Company News -

South Korea based JW Phar­ma­ceu­ti­cals re­cently pre­sented phase 1a/1b clin­i­cal trial re­sults for CWP291, a tar­get an­ti­cancer treat­ment that uses Wnt sig­nal­ing path­way, at the Amer­i­can So­ci­ety of He­ma­tol­ogy. The com­pany launched phase 1a clin­i­cal tri­als for CWP291 on 11 pa­tients with re­lapsed or re­frac­tory mul­ti­ple myeloma in the U.S. and Korea in 2015 while launch­ing phase 1b clin­i­cal tri­als that use CWP291 in com­bi­na­tion with lenalido­mide and dex­am­etha­sone on eight pa­tients last year. CWP291 is a first-in-class tar­get an­ti­cancer drug that in­hibits the growth of cancer cells and the mech­a­nism of Wnt/b-catenin, a sig­nal­ing sub­stance in­volved in cancer stem cells. The drug also has im­por­tant biomark­ers, such as in­creas­ing C/EBP ho­mol­o­gous pro­teins which is a ma­jor fac­tor of apop­to­sis of cancer cells. As a re­sult, 45 per­cent of the pa­tients main­tained a sta­ble dis­ease state with no pro­gres­sion in phase 1a tri­als, while 63 per­cent of phase 1b trial pa­tients saw a de­crease in M-pro­tein, an ab­nor­mal pro­tein pro­duced from the ma­lig­nant plasma cells, from their serum and urine.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.